Health ❯ Healthcare ❯ Medical Research ❯ Oncology

Lung Cancer

Fibroblasts Explain Why Lung Cancer Subtypes Respond Differently to Anti‑Angiogenic Drugs

The peer‑reviewed study points to TIMP‑1 as a pro‑angiogenic factor that could guide histotype‑specific treatment development pending clinical validation.

12 ARTICLES

4w ago

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

3 ARTICLES

last mo.

Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

4 ARTICLES

2mo ago

AI Pathomics Tool Beats PD-L1 at Predicting Lung Cancer Immunotherapy Benefit

3 ARTICLES

2mo ago

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

5 ARTICLES

6mo ago

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

4 ARTICLES

7mo ago

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

3 ARTICLES

8mo ago

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

3 ARTICLES

9mo ago

Preclinical Candidate AVJ16 Blocks IGF2BP1 to Halt Lung Tumor Growth in Models

3 ARTICLES

9mo ago

EML4-ALK V3 Proves More Aggressive and Less Drug-Sensitive Than V1 in New Study

3 ARTICLES

9mo ago

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

3 ARTICLES

9mo ago

Early ctDNA Test Flags Which LS-SCLC Patients Benefit From Consolidation Immunotherapy

3 ARTICLES

9mo ago

3-Week Radiotherapy Regimen Matches Survival, Cuts Severe Toxicity in Limited-Stage SCLC Trial

28 ARTICLES

9mo ago

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

4 ARTICLES

9mo ago

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

5 ARTICLES

9mo ago

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

3 ARTICLES

9mo ago

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

3 ARTICLES

last yr.

Comprehensive NGS Study Unveils Diverse Mutational Landscape in Lung Squamous Cell Carcinoma

4 ARTICLES

last yr.

AI Model Sybil Validated for Lung Cancer Risk Prediction in Diverse Populations

Lung Cancer

Fibroblasts Explain Why Lung Cancer Subtypes Respond Differently to Anti‑Angiogenic Drugs

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

AI Pathomics Tool Beats PD-L1 at Predicting Lung Cancer Immunotherapy Benefit

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Preclinical Candidate AVJ16 Blocks IGF2BP1 to Halt Lung Tumor Growth in Models

EML4-ALK V3 Proves More Aggressive and Less Drug-Sensitive Than V1 in New Study

Never miss stories about

Lung Cancer

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

Early ctDNA Test Flags Which LS-SCLC Patients Benefit From Consolidation Immunotherapy

3-Week Radiotherapy Regimen Matches Survival, Cuts Severe Toxicity in Limited-Stage SCLC Trial

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

Comprehensive NGS Study Unveils Diverse Mutational Landscape in Lung Squamous Cell Carcinoma

AI Model Sybil Validated for Lung Cancer Risk Prediction in Diverse Populations

Never miss stories about

Lung Cancer